GPX4 and neoplasm: To specifically drive tumour ferroptosis, a small‐molecule compound N6F11 was identified that can selectively induce the ubiquitination and degradation of GPX4 in tumour cells but not in immune cells, which can further enhance the function of CD8+ T cells and the sensitivity of tumour cells to immunotherapy.150